Translational research
BMBF-funded projects:
TARGET-FN– EudraCT-Nr.: 2016-002388-33
Fever is the most important clinical sign of infection in patients with an impared response after chemotherapy. To avoid serious complications from a bacterial infection, it is important to initiate effective antibiotic therapy as early as possible. The most commonly used antibiotic in hematology / oncology is the combination preparation piperacillin / tazobactam. The TARGET-FN study, as a prospective monocentric randomized-controlled treatment optimization trial, evaluates the benefits of piperacillin / tazobactam dosage adjusted to the plasma level of the drug. The aim of the study is to improve the response of antibiotic therapy in immunocompromised patients with cancer. The study was started in October 2016. The study is funded by the Federal Ministry of Education and Research (BMBF) via the Center for Sepsis Control and Care (CSCC) of the University Hospital Jena.
PL: Prof. von Lilienfeld-Toal
Funding: BMBF
Funding ID: BMBF 01EO1002
Funding Period: 01.08.2015 - 31.07.2018
IDES - Innovative Diagnostics for Pneumonia in Immunosuppression (IDES) in the Research Campus InfectoGnostics
Infections are the leading cause of death of patients with a immunosuppression due to cancer or immunosuppressive therapy. Pneumonia (infections of the lower respiratory tract) play a special role here. Currently, the diagnosis of infection in immunosuppressed patients is a particular challenge, as often risky and time-consuming procedures are required to make a safe diagnosis. As part of the research campus InfectoGnostics, several research institutions in Jena have joined forces to improve the diagnosis of infections in immunocompromised patients. Our working group is entrusted with the recruitment of the patient cohort, for which clinical data and biomaterials are collected and passed on to the cooperation partners. Aims of the study are the development of new and less burdensome and faster procedures for the diagnosis of infections in immunosuppressed patients as well as the answering of epidemiological questions. Recruitment began mid 2016. The study is designed as a prospective monocentric diagnostic study. Funding is provided by the Federal Ministry of Education and Research (BMBF) via the research campus InfectoGnostics in Jena.
PL: von Lilienfeld-Toal
Funding: BMBF
Funding ID: BMBF 13GW0096D
Funding Period: 01.02.2015 - 31.01.2020